|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100 ml |
inhalation vapour, liquid |
|
250 ml |
inhalation vapour, liquid |
||
|
|
|
1mg/ml - 250 ml |
inh. vapour liquid |
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
emulsion for infusion |
|
|
emulsion for infusion |
||
|
|
emulsion for infusion |
||
|
|
emulsion for infusion |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
120 mg 200 mg |
caps. prolong caps. prolong |
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
50 mg/ml-2 ml 100 mg / ml - 100 ml 100 mg / ml - 20 ml 100 mg / ml - 50 ml 100 mg / ml - 10 ml |
sol.inj. sol. sol. sol. sol. |
||
|
150 mg 200 mg |
tabl.prolong. tabl.prolong. |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
N02CC01 |
|
100 mg 50 mg |
tablets tablets |
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
(Sodium valproate 199.8 mg; Valproic acid 87 mg) |
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
250 mg 500 mg 1000 mg |
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
200 mg |
tabl. |
||
|
25 mg 50 mg 100 mg 200 mg |
dispersible tablet dispersible tablet dispersible tablet dispersible tablet |
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
100 mg/ml - 300 ml |
oral solution |
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
2mg |
tablets |
|
|
Carbidopa |
|
|
|
|
|
||
|
|
Decarboxylase |
|
|
|
|
Benserazide |
|
|
|
|
|
||
|
|
|
||
|
|
|
150/37,5/200 mg 50/12,5/200 mg |
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
2 mg |
Tabl. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
20 mg/ml ( 30mg/fl.) |
powd.inj. + solv. 1,2 ml x 1 |
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
50 mg |
tabl.film |
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
400 mg |
film-coated tablet |
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
3 mg 2 mg 1 mg 4 mg |
film coated tablet film coated tablet film coated tablet film coated tablet |
||
|
1 mg/ml - 100 ml |
sol. |
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
Молба за изключване |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
10 mg |
film-coated tablet |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
20 mg |
film coated tablet |
|
40 mg |
film coated tablet |
||
|
10 mg |
film coated tablet |
||
|
|
|
20 mg |
film coated tablet |
|
|
|
||
|
|
|
50 mg |
film coated tablet |
|
100 mg |
film coated tablet |
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
1ml - 215,2mg 5ml - 215,2 mg |
sol.inj./sol.inf. sol.inj./sol.inf. |
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
3g/15 ml - 15 ml |
sol.inj. |
||
|
3g/15 ml - 15 ml |
solution for injection |
||
|
2400 mg/5 g |
granules for oral solution |
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
Riboflavine sodium phosphate; Pyridoxine hydrochloride; Nicotinamide; Calcium pantothenate; Thiamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
N07BB04 |
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
24 mg 8 mg |
tabl. tabl. |
|
|
|
|
|